Last reviewed
7/8/26 → 7/10/26
Conviction●●●●○4 of 5
Research target$92.62Snapshot target
Thesis statusSTRENGTHENEDLast reviewed 7/10/26
Market cap$28.93BSnapshot value
Research history
See all DXCM changes ↗What changed
Conviction
1 → 4
Target
— → $92.62
Thesis status
NEEDS_MORE_DATA → STRENGTHENED
Last reviewed
Not reviewed → 7/8/26
Target
— → $92.62
Continuous glucose monitoring remains the core sensor platform for managing diabetes and expanding into broader consumer/healthspan monitoring; Dexcom is still the category leader with improving margins and product-extension momentum.
Dexcom G7 15 Day launch across all U.S. channels; Stelo feature expansion; FY2026 guidance raise for non-GAAP operating margin and adjusted EBITDA margin; continued international growth
Pricing pressure or competitive share loss to Abbott / Libre; launch execution failures for G7 15 Day or Stelo; reimbursement or regulatory setbacks; margin erosion if manufacturing expansion or channel mix disappoints
No fresh social sweep in this run; use primary-source earnings / filing evidence instead of chatter
Snapshot · 7/10/26🟢 Lean-Bull · ins-$5.2M · 13F 18+/7- · short↓0.24
Snapshot · 7/10/26